-
Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based VisualDx. This alliance aims to enhance the identification of individuals who may have blastic plasmacytoid dendritic cell neoplasm (BPDCN) by introducing artificial intelligence/machine learning (AI/ML) tools. Understanding BPDCNBPDCN is an aggressive orphan hematologic malignancy with…
-
SciClone and Menarini Submit NDA for Vaborem in China
•
China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of a New Drug Application (NDA) for Vaborem (meropenem vaborbactam) to the National Medical Products Administration (NMPA). The sought-after indication is complex urinary tract infections, including pyelonephritis. This submission marks a significant step in making this…
-
Menarini Group Expands Oncology Pipeline with Insilico Medicine License
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal with China-based AI drug discovery firm Insilico Medicine. The agreement grants Menarini global development and commercialization rights to a preclinical small molecule targeting oncology indications. This strategic move further expands Menarini’s oncology pipeline, leveraging Insilico’s…
-
Eli Lilly China Appoints Yan Qiong as Vice President of Diabetes Business Unit
•
Effective October 10, 2024, Yan Qiong will join the management team of Eli Lilly (NYSE: LLY) China as the vice president of the diabetes products business unit. She will report directly to Huzur Devletsah, the president and general manager of Lilly China. Yan Qiong brings nearly two decades of experience…
-
SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group
•
China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) and Italy-headquartered Menarini Group. While specific details of the partnership remain undisclosed, this alliance marks a significant step for all parties involved. Focus on Oncology and Infectious Diseases SciClone is dedicated…
-
Menarini and OrigiMed Partner on Pan-Cancer Single-Cell Diagnostic Platform
•
Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to co-develop a pan-cancer single-cell molecular diagnostic innovation platform. The collaboration leverages the respective platform advantages and integrates resources to work on a single-cell clinical molecular diagnosis project based on high-throughput next-generation sequencing technology. Moving forward,…
-
SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China
•
SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a licensing agreement with Italy-based Menarini Group regarding the latter’s novel drug Vaborem (meropenem). Under the agreement, SciClone will obtain development, regulatory, and commercialization rights to the antibacterial drug in China. SciClone will pay Menarini Group…
